December 1, 2015: Pharmaceutical prognosticators predict Gilead will remain a leader in providing therapies for hepatitis and HIV over the next decade, but also speculate the company will break ground in new treatment areas for oncology, respiratory and rheumatoid arthritis.
December 1, 2015: Complete Genomics will slash staff as the Bay Area company undergoes a transformation into a R&D-based company to support the clinical work of its China-based parent company, BGI, GenomeWeb reported Monday night.
December 1, 2015: Recent analysis of October sales records by IMS Health and RBC Capital Markets suggest that Paris-based Sanofi is quietly gaining market share in MS against Biogen. According to reports, Biogen had U.S. sales of its MS drug Tecfidera in October of $284M.
December 1, 2015: San Francisco-based Symic Biomedical recently closed on a Series A round worth $25M from Lilly Ventures, Eli Lilly's venture arm. Since setting up shop in 2012, Symic has raised more than $43M.